[1]
Vincent A.: Developments in autoimmune channelopathies, Autoimmunity Reviews 2013; 12: 678-681.
[2]
Lilleker J.B., et al.: VGKC complex antibodies in epilepsy: Diagnostic yield and Therapeutic implications. Seizure 2013; 22: 776-779.
[3]
Geva-Dayan K., et al.: Immunoglobulin Treatment for severe Childhood Epilepsy. Pediatr Neurol 2012; 46: 375-381.
[4]
Ravindra A., et al.: Hashimoto encephalopathy presenting as progressive myoclonus epilepsy syndrome J Eur Paediatr Neurol 2013; 17: 102-104.
[5]
Nafissa M., et al.: Hashimoto s encephalopathy: Identification and long-term outcome in children. J Eur Paediatr Neurol 2013; 17: 280-287.
[6]
Mirabelli-Badenier M.: Anti NMDAR encephalitis misdiagnosed as Hashimoto’s encephalopathy. J Eur Paediatr Neurol 2013; 17: 1-3.
[7]
Lin K.L., Wang H.-S.: Role of Antineuronal Antibodies in Children with Encephalopathy and Febrile Status Epilepticus. Pediatrics and Neonat 2014; 55: 161-167.
[8]
Ramanathan S., et al.: Autoimmune encephalitis: Recent updates and emerging challenges. Journal of Clinical Neuroscience 2013; 21 (5): 722-730.
[9]
Minetti C.: Autoimmune Epilepsy or exasperated search for the etiology seizures of unknown origin? Epilepsy& Behav 2012; 25: 440-441.
[10]
Quek A., et al.: Autoimmune Epilepsy. Arch Neurol 2012; 69: 582-593.
[11]
Hakan M., Gurcan M.D., et al.: A rewiew of the current use of rituximab in autoimmune disease. International Immunopharmacology 2009; 9: 10-25.
[12]
Souhel N., et al.: Extralimbic autoimmune encefalitis associated with glutamic acid decarboxylase antybodies; An underdiagnosed entity? Epilepsy& Behav 2011; 21: 306-313.
[13]
Miya K.: Anti-NMDAR autoimmune encephalitis. Brain & Dev 2013; xxx -xxx.
[14]
Chen S.-J.: Immune-Mediated Limbic encephalitis. Tip of the Iceberg in Childhood Autoimmune Epilepsy. Pediatrics and Neonatology 2013; 54: 217-218.
[15]
Suleiman J., Brilot F., Lang B., et al: Autoimmune epilepsy In children: Case series and proposed guidelines for identification. Epilepsia 2013; 54: 1036-1045.
[16]
Zuliani L., Graus F., Giometto B., et al.: Central nervous system neuronal surface antibody. Associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012; 83: 638-645.
[17]
Vincent A., Crino P.B.: Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia 2011; 52 (suppl. 3): 12-17.
[18]
Bien C.G., Scheffer I.E.: Autoantibodies and epilepsy. Epilepsia 2011; 52 (suppl. 3): 18-22.
[19]
Lancaster E., Dalmau J.: Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8: 380-390.
[20]
Sarkis R.A., Nehme R., Chemali Z.N.: Neuropsychiatry and seizure outcomes in nonparaneoplastic autoimmune limbic encephalitis. Epilepsy & Behav 2014; 39: 21-25.
[21]
Shin Y.-W., Lee S.-T., Shin J.-W., et al.: VGKC-complex/LGI1-antybody encephalitis: Clinical manifestations and response to immunotherapy. J Neuroimm 2013; 265: 75-81.
[22]
Mazurkiewicz-Bełdzinska M.: Padaczka o podłożu autoimmunologicznym i zapalnym. [w:] Postępy w diagnostyce i leczeniu chorób układu nerwowego u dzieci. Tom 13 (2013).
[23]
Bien C.G., Schram J.: Treatment of rasmussen encephalitis half a century after its initial description: Promising prospects and a dilemma. Epilepsy Research 2009; 86: 101-112.
[24]
Specchio N., et al.: Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis Brain & Development 2010; 32: 51-56.
[25]
Lancaster E., Martinez-Hernandez E., Dalmau J.: Encephalitis and antibodies to synaptic and neuron al cell surface proteins. Neurology 2011; 77: 179-189.
[26]
Ozkara C., Vigevano F.: Immuno- and antiinflammatory therapies in epileptic disorders. Epilepsia 2011; 52 (suppl. 3): 45-51.
Scholar Google
PubMed